This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    21/11/15

    Phase III trials of fluticasone propionate/salmeterol inhalers meet primary endpoints in asthma-Teva Pharmaceuticals

    Teva Pharmaceutical Industries announced positive top-line results from three Phase III clinical studies designed to evaluate the efficacy and safety...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    29/10/15

    Safety study results for Advair Diskus (salmeterol + fluticasone propionate) for Asthma- GlaxoSmithKline

    GlaxoSmithKline has announced results from the safety study AUSTRI (SAS115359) comparing Advair Diskus, a combination of the LABA salmeterol and...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/03/16

    AUSTRI study of Advair Diskus, (LABA, salmeterol and fluticasone propionate) in asthma published in New England Journal of Medicine- GlaxoSmithKline

    GlaxoSmithKline announced publication of results from the safety study, AUSTRI (SAS115359) in the New England Journal of Medicine (NEJM). The...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    07/05/17

    Study of Relvar Ellipta (fluticasone furoate/vilanterol) reports improvements in asthma patients versus standard care- GSK/Innoviva

    GlaxoSmithKline and Innoviva announced positive results from the innovative Salford Lung Study (SLS) of Relvar Ellipta (fluticasone furoate/vilanterol) in asthma,...

    Blue test tubes arranged in a line, disappearing into the background
    News
    12/11/24

    Results of phase III IRIDIUM study of Enerzair Breezhaler in asthma published in Lancet Respiratory Medicine.- Novartis

    Novartis announced that full results from the Phase III IRIDIUM study were published in The Lancet Respiratory Medicine. The primary endpoint results show that once-daily treatment with high- and medium-dose Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) demonstrated statistically significant improvements in lung function compared with once-daily QMF149 (indacaterol acetate and mometasone furoate [IND/MF]).

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    22/05/19

    Phase II data annonuced for once-daily, fixed dose combination asthma treatment

    Novartis announced that new phase II data for IND/GLY/MF (QVM 149), an investigational, once-daily, fixed dose combination asthma treatment containing...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    24/06/16

    EU CHMP recommends approval of Aerivio Spiromax (fluticasone propionate + salmeterol) for treatment of severe asthma and COPD in adults- Teva

    The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    24/06/16

    EU CHMP recommends approval of Airexar Spiromax (salmeterol xinafoate + fluticasone propionate) for treatment of severe asthma and chronic obstructive pulmonary disorder - Teva

    The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    01/02/17

    FDA approves AirDuo RespiClick (fluticasone propionate and salmeterol inhalation powder) and ArmonAir RespiClick (fluticasone propionate inhalation powder) to treat asthma.-Teva

    Teva Pharmaceutical Industries Ltd., announced that the FDA approved two products for adolescent and adult patients with asthma. These products,...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    30/09/19

    Novartis announces positive results from phase III IRIDIUM study of inhaled combination QVM 149 in patients with uncontrolled asthma

    Novartis announced that investigational, once-daily, inhaled QVM 149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate or IND/GLY/MF) was superior to...

    See more